Skip to main content
WeightCited

CLA ： Obesity

B

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dcla\u0026condition\u003Dobesity'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
結論

            
            
Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

            
            
        

    











    
    

        
        

            

  
Key Statistics





            


    

        
18

        
研究数

    

    

        
807

        
参加者数

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
グレード

    




        


        
        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
一般的な使用量

                

                    
                    

                        
general:

                        
3.2-6.4 g/day mixed isomers

                    

                    
                    

                        
bodycomposition:

                        
3.4 g/day (50:50 c9,t11:t10,c12 blend)

                    

                    
                    

                        
minimumeffective:

                        
3.2 g/day for ≥12 weeks

                    

                    
                

                
                

                    上限量： 6 g/day; higher doses may worsen insulin sensitivity
                

                
            

            

            

            
            

                推奨摂取タイミング： With meals; divide dose across 2-3 meals
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
報告されている副作用

                    
    
                        
                        
  • 
                            ⚠
                            GI discomfort
                        
    • 
                        
                        
  • 
                            ⚠
                            May worsen insulin sensitivity at high doses
                        
    • 
                        
                        
  • 
                            ⚠
                            Possible HDL reduction
                        
    • 
                        
                        
  • 
                            ⚠
                            Fatty liver (in some rodent studies)
                        
    • 
                        
                    

                

                

                
                

                    
既知の相互作用

                    
    
                        
                        
  • 
                            ●
                            Diabetes medications (may affect insulin sensitivity)
                        
    • 
                        
                        
  • 
                            ●
                            Blood thinners (theoretical)
                        
    • 
                        
                    

                

                

                
                

                    

                        耐容上限摂取量： 6 g/day; higher doses may worsen insulin sensitivity
                    

                

                
            

            

                サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does CLA help with Obesity?
            
        
        

            Based on 18 studies with 807 participants, there is moderate evidence from clinical studies that CLA may support Obesity management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much CLA should I take for Obesity?
            
        
        

            Studies have used various dosages. A commonly studied range is 3.2-6.4 g/day mixed isomers. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of CLA?
            
        
        

            Reported side effects may include GI discomfort, May worsen insulin sensitivity at high doses, Possible HDL reduction, Fatty liver (in some rodent studies). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for CLA and Obesity?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 807 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                
                

                
            

        

        

    


    
    












    

        FDAに関する免責事項:
        これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。